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Abstract
Background: The objective of this study was to compare the short-term effects of progesterone and corticosteroid
local injections in the treatment of female patients with carpal tunnel syndrome.
Methods: A randomized clinical trial was used for this study, 60 hands with mild and moderate Carpal Tunnel
Syndrome categorized in two groups were used for this study. Patients were treated with a single local injection of
triamcinolone acetonide in one group and single local injection of 17-alpha hydroxy progesterone in the other
group. Variables such as pain (based on Visual Analogue Scale), symptom severity and functional status (based on
Bostone/Levine symptom severity and functional status scale) and nerve conduction study were evaluated before
and 10 weeks after the treatments.
Results: Ten weeks after treatment, pain severity and median nerve sensory and motor latencies decreased while
patients’ functional status increased meaningfully in both groups. However, there were no meaningful differences
between two groups regarding mentioned variables. Pain severity was milder and duration of post-injection pain
was shorter in the corticosteroid group. The rates of patient satisfaction were also meaningfully higher in the
corticosteroid group.
Conclusions: Both treatments were effective in the short-term management of mild and moderate disease,
clinically and electrophysiologically. There were no significant differences in therapeutic effects between two
groups.
Trial registration: Current controlled trials IRCT2013101313442N4
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Background
Carpal tunnel syndrome (CTS) is the most common en-
trapment neuropathy in the upper limb which involves
the median nerve at the wrist [1]. Any factor increasing
the pressure in this region can cause edema, chronic in-
flammation and increased soft tissue thickness and com-
pressed median nerve. Patients commonly complain
about one or more symptoms of weakness, pain, numb-
ness, paresthesia, especially in the thumb, index and
middle fingers which are exacerbated during the night
time. this can lead to significant activity restriction, oc-
cupational disability and discomfort [2]. Generally treat-
ment is divided into two categories, conservative
treatment and surgical release of the median nerve. Sur-
gical treatment is usually used in severe forms of the dis-
ease and considering the potential side effects of such
treatment. conservative treatments should be used as far
as possible especially in mild and moderate forms [3, 4].
These treatments include local injections, medications
and physical modalities [5–9]. Existing scientific evi-
dence indicate that in many cases, local corticosteroid
injections cause significant relief in patients’ symptoms
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in mild to moderate CTS, However this effect is not per-
sistent for long term [10, 11]. Progesterone and its deriv-
atives are steroid hormones and apart from their role in
reproduction, they also have their neuroprotective ef-
fects in the central nervous system according to some
studies. Following different damages, Schwann cells start
to secrete progesterone which can play a significant role
in the acceleration of local inflammation relief and mye-
lin sheath regeneration [12–15]. There are receptors for
gonadal steroid hormones such as estrogen and proges-
terone located on the transverse ligament lining cells
and wrist synovial tissue. The number of such receptors
increases in patients with CTS. Therefore, it is postu-
lated that local progesterone injection could be effective
in conservative treatment of CTS. local corticosteroid
injection is the standard treatment known in non-
surgical management of CTS. This study was designed
to compare the effects of local injections of corticoste-
roids and progesterone in this disease.
Methods
Sixty (60) hands of bilateral cases, mild and moderate
idiopathic CTS were assessed during single-blinded ran-
domized clinical trial method. Inclusion criteria were as
follows: female patients aged between 18 to 60 years re-
ferred to physical and rehabilitation medicine clinics of
Shohadaye Tajrish and Modarres hospitals with mild and
moderate CTS diagnosed by electrodiagnostic studies.
Mild CTS was defined clinically as history of nocturnal
numbness, paresthesia and electrophysiologically as sen-
sory latency of longer than 3.6 ms with normal motor la-
tency (≤4.2 ms). Moderate CTS was defined clinically as
diurnal and nocturnal paresthesia without evidence of
atrophy and weakness in thenar muscles and electro-
physiologically as sensory latency of longer than 3.6 ms
and prolonged motor latency (4.3–6 ms). Exclusion cri-
teria were pregnancy, underlying metabolic diseases such
as diabetes mellitus, thyroid diseases, rheumatoid arth-
ritis, history of local corticosteroid injection, severe the-
nar atrophy, evidence of concomitant neuropathy or
radiculopathy and patient’s desire to leave the study.
This research study was approved by the Ethics Com-
mittee of ShahidBeheshti University of Medical Sciences,
and conducted in accordance with the principles of the
Declaration of Helsinki (reference number:400/8770).
Also it has was registered in IRCT (Iranian registry of
clinical trials).
The methods of progesterone and corticosteroid injec-
tion as well as benefits and probable adverse effects were
presented by a physiatrist to all patients. The informa-
tions listed above were given to the participants in a
written form and all participants who signed the consent
form were also included in this study.
Randomization
We used simple random sampling. All hands received
a number the by using random numbers table they
were allocated to two groups: Progesterone and
corticosteroid
Type of study design was parallel groups. Equal alloca-
tion between treatment arms was performed. The hands
were classified randomly in groups A) progesterone and
B)corticosteroid . Random allocation sequence and as-
signments of hands to interventions were performed by
a physiatrist.
Table 1 Demographic and electrodiagnostic characteristics at the beginning of the study in corticosteroid and progesterone groups
Variable























*chi square test :P value >0.05
#t test :P value > 0.05















Corticosteroid 5 ± 2.7 2.23 ± 1.30 P = 0.0001 1.54 ± 0.50 1.17 ± 0.21 P = 0.0001 2.51 ± 0.61 2.07 ± 1.95 P = 0.0001
Progesterone 4.8 ± 2.4 2.29 ± 1.75 P = 0.0001 1.86 ± 0.56 1.37 ± 0.49 P = 0.0001 2.42 ± 0.67 1.70 ± 0.50 P = 0.0001
*paired t test
P value between groups: P value > 0.05(t test)
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Blinding
Assignments of hands after randomization were
placed in sealed envelopes. To ensure blinding, as-
signments were disclosed to analysis only after the re-
sults had been delivered. The patients were unaware
of the type of treatment applied. The assessors were
unaware of the type of treatment being applied to
their hands but the physician was not blinded with
respect to treatment.
For all participants, variables of pain (based on VAS),
symptom severity and functional status (based on Bos-
tone/Levine symptom severity scale and Bostone/Levine
functional status scale, respectively) and sensory and
motor distal latencies (using nerve conduction study)
were evaluated. Bostone/Levine symptom severity scale
(SSS) was used to evaluate the severity of symptoms in-
cluding pain, paresthesia and weakness during the past
2 weeks. It contained 11 questions with five choices for
each one starting from no symptom to very high in se-
verity so that more severe symptoms gained more
scores[16]. Bostone/Levine functional status scale (FSS)
is used to evaluate the patient’s functional status. It con-
tains eight questions about the patient’s activity for the
past 2 weeks and each activity is scored in a scale of five,
such that higher scores indicate more inappropriate
functional status [16]. Bostone/Levine scales have been
validated for Iranian patients [17]. To evaluate pain se-
verity based on visual analogue scale (VAS), patients
mark the location on the 10-centimeter line correspond-
ing to the amount of pain they experienced. The point
of “no pain” equals to zero and the point of “maximum
pain” equals to 10. In electrodiagnostic studies, median
sensory and motor distal latencies were evaluated. Me-
dian sensory nerve action potential (SNAP) evaluation
was done antidromically. The recorder electrode was
fixed on the third digit with active-reference distance
of 4 cm [18]. Stimulation was applied from the wrist
with 14 cm distance from the active electrode. Device
sensitivity and sweep speed were set on 20 μv and
2 ms/div, respectively and peak latency was used for
measuring the latency. For evaluating the median
compound motor action potential (CMAP), recorder
electrode was fixed on the abductor pollicis brevis
(APB) muscle in such a way that an active electrode
was positioned on the most prominent part of the
muscle and the reference electrode was positioned on
the palmar aspect of the first metacarpophalangeal
joint. The median nerve was stimulated supramaxi-
mally at a point of 8 cm proximal to the active elec-
trode (measured angularly along the Median nerve
course). Device sensitivity and sweep speed were set
on 1 mv and 2 ms/div, respectively and onset latency
was used for measuring the latency [18]. Hands were
divided into two groups (A and B) randomly. Hands
in group A received a single local injection of 0.5 ml
triamcinolone acetate (40 mg/ml) and 0.5 ml lido-
caine (2 %) with a 2-ml syringe using 23-gauge nee-
dle. Hands in group B received a single local
injection of 0.5 ml 17-alpha hydroxy progesterone
(500 mg/2 ml) and 0.5 ml lidocaine (2 %) with the
same syringe and needle as group A. Injections were
done at 1 cm proximal to wrist crease between the
tendons of palmarislongus and flexor carpi radialis
with a 45 degree angle. Ten weeks after the injec-
tions, patients were visited again and mentioned
questionnaires were fulfilled and nerve conduction
studies were performed again. For comparing two
groups’ means and frequencies, t test and chi square
were used, respectively. Finally, the results were ana-
lyzed using SPSS version 17.
Table 3 Median nerve sensory and motor latencies 10 weeks after the treatment in both groups
Group Variable
distal sensory latency 1 distal sensory latency 2 *Pv within group motor onset latency 1 motor onset latency 2 *Pv within group
Corticosteroid 4.25 ± 0.59 3.94 ± 0.38 P = 0.0001 4.33 ± 0.58 4.04 ± 0.40 P = 0.003
Progesterone 4 ± 0.33 3.85 ± 0.42 P = 0.009 4.15 ± 0.36 4.02 ± 0.49 P = 0.014
*paired t test
P value between groups: P value > 0.05(t test)
Table 4 Disease severity based on electrodiagnostic findings before and 10 weeks after the treatment in both groups
Group Variable
Severity1(%) Severity2(%)
Mild Moderate Normal Mild Moderate * p.v within group
Progesterone 53.6 % 46.4 % 25 % 58.3 % 16.7 % 0.32
Corticosteroid 46.9 % 53.1 % 20 % 60 % 20 % 0.57
Total 50 % 50 % 22.2 % 59.3 % 18.5 %
*chi square test
P value between groups: P value > 0.05 (chi square test)
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Results
Sixty hands with CTS were included in this study
(32 hands in the corticosteroid group and 28 hands
in the progesterone group). with fifty four hands
remaining at the end of the study (30 hands in the
corticosteroid group and 24 hands in the progester-
one group).
Pre-intervention findings
Both groups were congruent and similar in mean age,
duration and severity of the pain before treatment, sen-
sory and motor latencies and symptom severity based on
SSS with no meaningful difference was detected. Pa-
tients’ functional status based on FSS was lower in the
progesterone group. Demographic variables and nerve
conduction characteristics at the beginning of the study
in both groups are shown in Table 1.
Ten-week post-intervention changes (Tables 2 and 3)
Pain (based on VAS), symptom severity (based on Bos-
ton SSS), functional status (based on Boston FSS) and
electrodiagnostic variables were improved upon in both
groups significantly. However, there was no meaningful
difference between the two groups when compared.
Patients were evaluated for disease severity based on
electrodiagnostic studies before and 10 weeks after treat-
ment. The NCS became normal in 20 % of patients in
the corticosteroid group and 25 % of patients in the pro-
gesterone group (totally 22.2 %) at the end of the study
(Table 4). There was no statistical difference between the
two groups in the disease severity changes.
There was some degree of post-injection pain in most
patients in the progesterone group. Post-injection pain se-
verity (based on VAS) and duration in the progesterone
group was more than the corticosteroid group (p = 0.001).
Patient satisfaction injection was meaningfully greater in
the corticosteroid group 10 weeks after the injection was
assessed (p = 0.005). There was no meaningful relationship
between patient satisfaction and post-injection pain severity
and duration and also between symptom severity and func-
tional status improvement and sensory and motor latency
changes.
Discussion
Multiple non-surgical treatments have been proposed
for the treatment of CTS including oral medications
such as nonsteroidal anti-inflammatory drugs (NSAIDs),
oral corticosteroids and supplemental vitamin B6 and
physical modalities such as ultrasound, low-power laser,
polychromatic polarized light (Bioptron), exercise ther-
apy, nerve mobilization, acupuncture, splinting and local
steroid injection. New treatments under investigation
are local insulin and progesterone injections. Hydroxy
progesterone is a natural progesterone hormone
metabolite which have been shown in different studies
to have neuroprotective effects in central and peripheral
nervous systems [12–14, 19]. It has been shown that
Schwann cells start to secrete these steroids in response
to peripheral nervous system injuries which leads to
Schwann cell proliferation and increased myelin synthe-
sis [20–22]. However there are limited studies about the
effects of progesterone and its derivatives in the treat-
ment of entrapment neuropathies these include com-
parison between local injection of triamcinolone with
17-hydroxy progesterone in mild carpal tunnel syn-
drome. In this study patients were divided into two
groups with 8 participants in each one. Patients were
randomly allocated to one of two groups: (I) single
corticosteroid (triamcinolone acetonide, 20 mg/
0.5 ml,Triamvigi, Fisiopharma), or (II) single synthetic
derivative of PROG (17HPC, 85 mg/0.5 ml, Lentogest,
A.M.S.A.) Patients’ symptoms based on VAS pain scale,
Boston questionnaires for SSS and FSS, and electrodiag-
nostic findings were all evaluated 1 and 6 months after
the injections. Pain severity in both groups decreased
after 1 month and there was no meaningful difference
between two groups. However, this effect remained only
in the progesterone group after 6 months. Improved
functional scales were only seen in progesterone group
while improved electrodiagnostic findings were only
demonstrated in corticosteroid group, implicating the
long term effect of local progesterone injection on clin-
ical improvement of CTS compared to corticosteroid
[23]. In our study mild and moderate CTS were evalu-
ated but in previous study only subjects with mild CTS
were selected and dosage of injected drug was different
from. In our study, in 10-weeks follow up, variables of
pain, symptom severity (SSS), functional status (FSS)
and electrodiagnostic findings were improved signifi-
cantly in both groups with no meaningful difference be-
tween the two groups. No statistical difference was
shown in severity change based on electrodiagnostic cri-
teria in any of the groups.
Multiple studies have been performed about local cor-
ticosteroid injection in CTS treatment. In a study camed
out in 2011, local injection of triamcinolone was com-
pared with procaine. Pain was improved more in cor-
ticosteroid group after 2 months. However, after
6 months of follow up no meaningful difference was
seen[24]. In another study, 69 patients were divided into
two groups. In one group, local injection of triamcino-
lone was administered while in the other group, local in-
jection of saline (as placebo) was administered and
patients’ symptoms were evaluated using SSS and FSS.
In the short-term follow up, significant improvement
was seen in the first group after 1 month. The main
mechanism of action of steroid in CTS treatment is
through decrease in flexor retinaculum inflammation
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and swelling and the resulting decrease in median nerve
pressure [25]. In a review article published in Cochrane
(2007), 12 studies including 671 patients were evaluated
and it was shown that local corticosteroid injection leads
to obvious clinical improvement in patients in 1-month
follow up compared to placebo. However, no significant
improvement was detected after 1 month and it was rec-
ommended that more studies were needed to be per-
formed to determine the long-term effects of steroid
injections in mild and moderate CTS [11]. In our study,
all of the variables of pain, symptom severity, functional
status and electrodiagnostic findings significantly im-
proved after 10 weeks of follow up. According to some
studies, the probable mechanism of action of progester-
one on patients’ pain and symptoms may be due to de-
crease in pain and paresthesia generating impulses
through regulating voltage-gated sodium channels, the
amount of calcium flow and Na/K ATPase pump activ-
ity. On the other hand, progesterone has influence on
opioid receptors located on non-myelinated sensory
nerves. This causes an increase in the peripheral tissue
inflammatory processes thereby inhibiting the increase
in P substance; therefore leading to pain decrease. Pro-
gesterone’s effect on improved myelin synthesis, is the
main primary pathology in CTS. This is the probable ex-
planation for improved electrodiagnostic findings in
such patients.
Conclusions
According to this study, both corticosteroid and proges-
terone are effective in short-term improvement of elec-
trodiagnostic and clinical findings of mild and moderate
CTS. However, there is no statistical difference between
the two groups. Due to the probable patients drop out
in long term follow up, 10 week follow up was consid-
ered for this study. The lack of control group and rather
small sample size are among other study limitations. In
order to gain more definite results, performing a study
with larger sample size and longer follow up period with
including the control group with no therapeutic inter-
vention and also objective evaluation of patients’ func-
tional status such as grip power assessment seem
necessary.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conceived and designed the experiments: SAR, SS and MHB. Analyzed the
data: SAR and SS. Wrote the first draft of the manuscript: SAR and SS.
Contributed to the writing of the manuscript: MHB. Agree with manuscript
results and conclusions: SAR and MHB. Jointly developed the structure and
arguments for the paper: SAR. Made critical revisions and approved final
version: SAR and MHB. All authors reviewed and approved of the final
manuscript.
Acknowledgements
We appreciate Dr. Leyla Sedighipour for her valuable help in editing the final
version of the article; Mrs. Mehrnaz Mehrabi, assistant researcher at Clinical
Research and Development Center, Shahid Modarres Hospital, for assisting in
submission of study in IRCT; and Zahra Razzaghi, statistician, for extraordinary
cooperation with us in this study.
Author details
1Physical Medicine and Rehabilitation research center, Shahid Beheshti
University of Medical Sciences , Tehran, Iran. 2Clinical research development
center of Shahid Modarres hospital, Shahid Beheshti University of Medical
Sciences, Tehran, Iran. 3Clinical research development center of Shahid
Modarres hospital, Shahid Beheshti University of Medical Sciences, Tehran,
Iran.
Received: 4 April 2015 Accepted: 4 October 2015
References
1. Burke FD. Carpal tunnel syndrome: reconciling “demand management” with
clinical need. J Hand Surg Br. 2000;25(2):121–7.
2. Nathan PA, Meadows KD, Istvan JA. Predictors of carpal tunnel syndrome:
an 11-year study of industrial workers. J Hand Surg Am. 2002;27(4):644–51.
3. Benson LS, Bare AA, Nagle DJ, Harder VS, Williams CS, Visotsky JL.
Complications of endoscopic and open carpal tunnel release. Arthroscopy.
2006;22(9):919–24. 24 e1-2.
4. Braun RM, Rechnic M, Fowler E. Complications related to carpal tunnel
release. Hand Clin. 2002;18(2):347–57.
5. Marshall S, Tardif G, Ashworth N. Local corticosteroid injection for carpal
tunnel syndrome. Cochrane Database Syst Rev. 2002;4:CD001554.
6. Piazzini DB, Aprile I, Ferrara PE, Bertolini C, Tonali P, Maggi L, et al. A
systematic review of conservative treatment of carpal tunnel syndrome. Clin
Rehabil. 2007;21(4):299–314.
7. Raeissadat SA, Rayegani SM, Rezaei S, Sedighipour L, Bahrami MH, Eliaspour
D, et al. The effect of polarized polychromatic noncoherent light (bioptron)
therapy on patients with carpal tunnel syndrome. J Lasers Med Sci.
2014;5(1):39–46.
8. Rayegani SM, Bahrami MH, Eliaspour D, Raeissadat SA, ShafiTabar M,
Sedihgipour L, et al. The effects of low intensity laser on clinical and
electrophysiological parameters of carpal tunnel syndrome. J Lasers Med
Sci. 2013;4(4):182–9.
9. Raeissadat A, Soltani RZ. Study of long term effects of laser therapy versus
local corticosteroid injection in patients with carpal tunnel syndrome.
J Lasers Med Sci. 2010;1:24–30.
10. Hagebeuk EE, de Weerd AW. Clinical and electrophysiological follow-up
after local steroid injection in the carpal tunnel syndrome. Clin
Neurophysiol. 2004;115(6):1464–8.
11. Marshall S1, Tardif G, Ashworth N. Local corticosteroid injection for carpal
tunnel syndrome. Cochrane Database Syst Rev. 2007 18;(2):CD001554
12. De Nicola AF, Labombarda F, Gonzalez Deniselle MC, Gonzalez SL, Garay L,
Meyer M, et al. Progesterone neuroprotection in traumatic CNS injury and
motoneuron degeneration. Front Neuroendocrinol. 2009;30(2):173–87.
13. Schumacher M, Guennoun R, Stein DG, De Nicola AF. Progesterone:
therapeutic opportunities for neuroprotection and myelin repair. Pharmacol
Ther. 2007;116(1):77–106.
14. De Nicola AF, Gonzalez SL, Labombarda F, Gonzalez Deniselle MC, Garay L,
Guennoun R, et al. Progesterone treatment of spinal cord injury: effects on
receptors, neurotrophins, and myelination. J Mol Neurosci. 2006;28(1):3–15.
15. Toesca A, Pagnotta A, Zumbo A, Sadun R. Estrogen and progesterone
receptors in carpal tunnel syndrome. Cell Biol Int. 2008;32(1):75–9.
16. Levine DW, Simmons BP, Koris MJ, Daltroy LH, Hohl GG, Fossel AH, et al. A
self-administered questionnaire for the assessment of severity of symptoms
and functional status in carpal tunnel syndrome. J Bone Joint Surg Am.
1993;75(11):1585–92.
17. Rezazadeh A, Bakhtiary A, Samaei A, Moghimi J. Validity and reliability of the
Persian Boston questionnaire in Iranian patients with carpal tunnel
syndrome. Koomesh. 2014;15(2):138–45.
18. Sitruk-Ware R, El-Etr M. Progesterone and related progestins: potential new
health benefits. Climacteric. 2013;16 Suppl 1:69–78.
19. Daniel D. Electrodiagnostic medicine. 2nd ed. Philadelphia, PA:
Honley&Belfus; 2002.
Bahrami et al. BMC Musculoskeletal Disorders  (2015) 16:322 Page 5 of 6
20. Koenig HL, Schumacher M, Ferzaz B, Thi AN, Ressouches A, Guennoun R,
et al. Progesterone synthesis and myelin formation by Schwann cells.
Science. 1995;268(5216):1500–3.
21. Roglio I, Bianchi R, Gotti S, Scurati S, Giatti S, Pesaresi M, et al.
Neuroprotective effects of dihydroprogesterone and progesterone in an
experimental model of nerve crush injury. Neuroscience. 2008;155(3):673–85.
22. Burke FD, Ellis J, McKenna H, Bradley MJ. Primary care management of
carpal tunnel syndrome. Postgrad Med J. 2003;79(934):433–7.
23. Ginanneschi F, Milani P, Filippou G, Mondelli M, Frediani B, Melcangi RC,
et al. Evidences for antinociceptive effect of 17-alpha-hydroxyprogesterone
caproate in carpal tunnel syndrome. J Mol Neurosci. 2012;47(1):59–66.
24. Karadas O, Tok F, Ulas UH, Odabasi Z. The effectiveness of triamcinolone
acetonide vs. procaine hydrochloride injection in the management of carpal
tunnel syndrome: a double-blind randomized clinical trial. Am J Phys Med
Rehabil. 2011;90(4):287–92.
25. Peters-Veluthamaningal C, Winters JC, Groenier KH, Meyboom-de Jong B.
Randomised controlled trial of local corticosteroid injections for carpal
tunnel syndrome in general practice. BMC Fam Pract. 2010;11:54.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bahrami et al. BMC Musculoskeletal Disorders  (2015) 16:322 Page 6 of 6
